Back

Granzyme B-based CAR T cells block metastasis by eliminating circulating tumor cells

Sun, B.; Guo, J.; Yang, D.; Hu, Q.; Ma, H.; Tian, P.; Liu, N.; Lv, L.; Yan, L.; Hao, D.; Fu, M.; Gou, H.; Cao, D.; Liu, D.; Chen, N.; SHI, P.; Li, W.; Zhao, X.

2024-03-19 immunology
10.1101/2024.03.18.585442 bioRxiv
Show abstract

Chimeric antigen receptor (CAR) T cells have limited efficacy against solid tumors due to the hostile microenvironment. Circulating tumor cells (CTCs) are essential to metastasis, which is the cause of most of cancer-related death. Here, we generated GrB-CAR T cells targeting membrane-bound HSP70 (mHSP70), a highly tumor-specific antigen detected in numerous cancers. GrB-CAR T cells exhibited potent cytotoxicity against a broad spectrum of cancer cell lines and stem-like cancer cells in vitro and effectively inhibited xenograft tumor growth in vivo. Importantly, GrB-CAR T cells markedly decreased the number of CTCs and, therefore, hindered cancer metastasis in spontaneous metastasis models with uncontrollable primary tumor growth, a scenario commonly encountered in clinical trials of CAR T therapies for solid tumors. Furthermore, despite the 100% homology between human and macaque HSP70 protein, the autotransplantation of macaque T cells expressing human GrB-CAR did not cause any obvious toxic effects. These results not only demonstrate GrB-CAR T cells as a safe and effective tactic with broad-spectrum anticancer activity, but also offer strong experimental evidence and proof-of-concept validation for CAR T cell-mediated metastasis inhibition by targeting CTCs.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Cancer Letters
35 papers in training set
Top 0.1%
39.4%
2
eLife
5828 papers in training set
Top 10%
9.8%
3
Molecular Therapy
81 papers in training set
Top 0.3%
5.5%
50% of probability mass above
4
Cancer Immunology Research
35 papers in training set
Top 0.2%
5.5%
5
Theranostics
37 papers in training set
Top 0.2%
3.2%
6
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.2%
2.7%
7
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.8%
2.6%
8
Nature Communications
5641 papers in training set
Top 42%
2.1%
9
iScience
1154 papers in training set
Top 18%
1.7%
10
Advanced Science
286 papers in training set
Top 6%
1.3%
11
Frontiers in Immunology
638 papers in training set
Top 7%
1.1%
12
Journal of Clinical Investigation
179 papers in training set
Top 5%
1.1%
13
OncoImmunology
24 papers in training set
Top 0.5%
1.0%
14
Science Advances
1243 papers in training set
Top 28%
1.0%
15
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.6%
0.9%
16
Cell Research
51 papers in training set
Top 1%
0.8%
17
JCI Insight
277 papers in training set
Top 8%
0.8%
18
Cancer Immunology, Immunotherapy
12 papers in training set
Top 0.3%
0.6%
19
Protein & Cell
25 papers in training set
Top 0.6%
0.6%
20
Cell Reports Medicine
153 papers in training set
Top 6%
0.6%
21
Cell Discovery
57 papers in training set
Top 1%
0.6%
22
Antibody Therapeutics
16 papers in training set
Top 0.3%
0.6%
23
Cancer Research
130 papers in training set
Top 3%
0.6%
24
Communications Biology
993 papers in training set
Top 35%
0.6%